- Home
- ESNT vs FBIOP Comparison
ESNT vs FBIOP Comparison
Compare ESNT & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- FBIOP
- Stock Information
- Founded
- ESNT 2008
- FBIOP N/A
- Country
- ESNT Bermuda
- FBIOP United States
- Employees
- ESNT N/A
- FBIOP 101
- Industry
- ESNT Property-Casualty Insurers
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- ESNT Finance
- FBIOP Health Care
- Exchange
- ESNT Nasdaq
- FBIOP Nasdaq
- Market Cap
- ESNT N/A
- FBIOP N/A
- IPO Year
- ESNT 2013
- FBIOP N/A
- Fundamental
- Price
- ESNT $62.25
- FBIOP $7.50
- Analyst Decision
- ESNT Buy
- FBIOP
- Analyst Count
- ESNT 6
- FBIOP 0
- Target Price
- ESNT $63.67
- FBIOP N/A
- AVG Volume (30 Days)
- ESNT 739.5K
- FBIOP N/A
- Earning Date
- ESNT 08-08-2025
- FBIOP N/A
- Dividend Yield
- ESNT 1.97%
- FBIOP N/A
- EPS Growth
- ESNT N/A
- FBIOP N/A
- EPS
- ESNT 6.85
- FBIOP N/A
- Revenue
- ESNT $1,268,306,000.00
- FBIOP N/A
- Revenue This Year
- ESNT $5.48
- FBIOP N/A
- Revenue Next Year
- ESNT $3.59
- FBIOP N/A
- P/E Ratio
- ESNT $9.17
- FBIOP N/A
- Revenue Growth
- ESNT 5.28
- FBIOP N/A
- 52 Week Low
- ESNT $51.61
- FBIOP N/A
- 52 Week High
- ESNT $65.34
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- ESNT 72.92
- FBIOP 50.80
- Support Level
- ESNT $56.67
- FBIOP $6.99
- Resistance Level
- ESNT $58.17
- FBIOP $7.60
- Average True Range (ATR)
- ESNT 1.07
- FBIOP 0.34
- MACD
- ESNT 0.77
- FBIOP 0.06
- Stochastic Oscillator
- ESNT 98.72
- FBIOP 83.65
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.